ROCO
4195
Market cap37mUSD
Jun 04, Last price
17.00TWD
Name
Genomics Bioscience & Technology Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Genomics BioSci & Tech. Co.,Ltd. specializes in providing a comprehensive array of services within the field of genomic sequencing. Its core offerings encompass standard and intricate DNA sequencing, including TAF-certified options, with clients also benefiting from complimentary sequencing primer and primer walking services. Beyond sequencing, the company is proficient in synthesizing peptides, genes, and oligonucleotides. Furthermore, its analytical capabilities extend to crucial laboratory services such as sample preparation, gene expression analysis, genotyping, DNA methylation analysis, and microbial identification. The firm also delivers advanced sequencing solutions, including genome-level, targeted, gene regulation, and metagenomic sequencing, alongside cutting-edge third-generation sequencing technologies. To support these services, it offers integrated sequencing platforms and streamlined workflows. Additionally, Genomics BioSci & Tech. Co.,Ltd. provides specialized diagnostic screenings, such as non-invasive prenatal testing (NIPT), spinal muscular atrophy (SMA) carrier screening, and fragile X syndrome premutation screening. Established in 2001, the company's headquarters are located in New Taipei City, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||